Yuanteng Jeff Li, MD, RhMSUS, FACR
Department of General Internal Medicine, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2017 | UTHSC McGovern Medical School, Houston, Texas, US, MD |
| 2012 | The University of Texas at Austin, Austin, Texas, US, Bachelor of Science Biochemistry, BS |
| 2012 | The University of Texas at Austin, Austin, Texas, US, Minor, Business Administration |
| 2012 | The University of Texas at Austin, Austin, Texas, US, Bachelor of Arts, BA |
Postgraduate Training
| 2024-null | LeadingOTHERS, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2022-null | Postgraduate Fellow, LeadingSELF, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2022-2024 | Postgraduate Fellow, Clinical Research Curriculum, UTHSC McGovern Medical School, Houston, Texas |
| 2021-2022 | Chief Fellow, Rheumatology Fellowship, UTHSC McGovern Medical School, Houston, Texas |
| 2020-2022 | Clinical Residency, Rheumatology Fellowship, UTHSC McGovern Medical Scholl, Houston, Texas |
| 2017-2020 | Clinical Internship, Internal Medicine Residency, UTHSC McGovern Medical School, Houston, Texas |
| null-2020 | Certificate in Healthcare Administration, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| null-2022 | Certificate in Physician Educator, UTHSC McGovern Medical School, Houston, Texas |
| null-2023 | Postgraduate Fellow, Quality Bone Densitometry: Performance, Interpretation, and Clinical Application for Clinicians Course, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| null-2024 | Postgraduate Fellow, Capillaroscopy Conference for scleroderma, Vanderbilt University, Nashville, TN |
| null-2024 | Certificate in Leading Clinical Research, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| null-2026 | CERTain Workshop: Observational Studies, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| null-null | Rheum with a Review, American College of Rheumatology Mentorship Program |
Licenses & Certifications
| 2023 | Florida Board of Medicine |
| 2023 | Arizona Board of Medical Examiners |
| 2023 | Tennessee Board of Medical Examiners |
| 2023 | Louisiana State Board of Medical Examiners |
| 2023 | Alabama Board of Medical Examiners |
| 2023 | Oklahoma State Board of Medical Licensure |
| 2023 | Musculoskeletal Ultrasound Certification in Rheumatology |
| 2022 | American Board of Internal Medicine Rheumatology Board |
| 2020 | American Board of Internal Medicine |
| 2019 | Texas Medical License |
| null | Mississippi State Board of Medical Licensure |
| null | Georgia Composite Medical Board |
Experience & Service
Administrative Appointments/Responsibilities
Member, RIO Task Force, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Representative for MD Anderson for Baylor Rheumatology Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Contributor, IOTOX Guidelines for Rheumatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Lead, Journal Club for Rheumatology Section, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - 2026
Lead, Difficult Case Conference, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - 2026
Other Professional Positions
Representative for MD Anderson for Baylor Rheumatology Fellowship, Baylor College of Medicine, Houston, Texas, 2024 - Present
Lead, Journal Club for Rheumatology Section, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present
Member, RheumPAC Committee, American College of Rheumatology, Washington D.C, 2022 - Present
Intramural Institutional Committee Activities
Member, Data and Biospecimen Access Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Institutional Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Sedation and Procedure Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2024
Extramural Institutional Committee Activities
Member, IOTOX Research Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Data Quality Subcommittee RADIOS, multi center irAE cohort, University of Texas MD Anderson Cancer Center, 2025 - Present
Member, IOTOX Clinical Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, RheumPAC Committee, American College of Rheumatology, 2022 - 2025
Honors & Awards
| 2026 - Present | ACR/EULAR/APLAR Research Exchange Travel Award, International Rheumatology Award |
| 2025 | Awesome Job Award: Caring, University of Texas MD Anderson Cancer Center |
| 2024 - 2025 | Top Performer: top 10% on CAHPS measures, University of Texas MD Anderson Cancer Center |
| 2020 | Alpha Omega Alpha |
| 2018 - 2019 | 110% Outstanding Resident of the Month |
| 2014 | National Institute of Diabetes, Digestive and Kidney Disease Summer Research Grant |
| 2012 | Phi Beta Kappa |
| 2011 | Marie Smith Regents Endowed Scholarship in Chemistry |
| 2011 | Edmund Thornton Miller Presidential Scholarship in Economics |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. IOTOX Clinical Education: ICI-induced Raynaud’s syndrome. Houston, Texas, US.
- 2025. Rheum irAE. Lecture for Fellows. Houston, Texas, US.
- 2025. A Safety Analysis based on Platelets in Arthrocentesis and Joint Injections in Cancer Patients. DoIM Research Symposium. Houston, Texas, US.
- 2025. Common Upper Extremity MSK problems. APP Lecture. Houston, Texas, US.
- 2023. Acute Onset of CNS vasculitis related to Pembrolizumab after Peritoneeal shunt Revision. Poster. IOTOX Clinical Education Symposium. Houston, Texas, US.
- 2023. Rheumatology Update. 2023 IOTOX Clinical Education Symposium. Houston, Texas, US.
- 2023. Peresolimab for Adults with Rheumatoid Arthritis for General Internal Medicine. Invited. Department Journal Club. Houston, Texas, US.
- 2023. Review of Rheumatoid Arthritis for Baylor College of Medicine Residency. Invited. Houston, Texas, US.
- 2023. A diagnostic approach to monoarthirtis. Invited. APP Lecture. Houston, Texas, US.
- 2019. To Improve Resident Awareness of Stain Prescriptions in Chronic Kidney Disease Patients at Lyndon B. Johnson Renal Clinic. Conference. UTHSC McGovern Medical School Quality Improvement Fair. Houston, TX, US.
- 2014. A PKM2 Signature in the Failing Heart. Poster. Peer-reviewed conference presentation. Houston, Texas, US.
Regional Presentations
- 2014. Oral Presentation "A PKM2 signature in the Failing Heart". Conference. American Medical Association Research Symposium. Dallas, TX, US.
National Presentations
- 2025. A Retrospective Safety Analysis based on Platelets in Arthrocentesis and Joint injections in Cancer Patients - Infection-related Rheumatic Disease Poster. Poster. ACR Convergence. Chicago, Illinois, US.
- 2025. Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T Cells Contribute to Recurrent Immune Checkpoint Inhibitor Mediated Inflammatory Arthritis. Poster. ACR Convergence. Chicago, Illinois, US.
Selected Publications
Peer-Reviewed Articles
- Keam S, Li YJ, Chu Y, Tayar JH, Lu H, Wu M, Agarwal SK, Jain N, Msaouel P, Diab A, Wang L, Haymaker C, Nurieva R, Kim ST. Immune hallmarks of recurrent immune checkpoint inhibitor-mediated inflammatory arthritis. Cancer Immunol Res, 2026. e-Pub 2026. PMID: 42536056.
- Li YJ, Lopez-Olivo MA, Geng Y, Tayar JH, Suarez-Almazor ME. Dose reduction and discontinuation of non-tumor necrosis factor (TNF) biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for people with rheumatoid arthritis in remission or low disease activity. Cochrane Database Syst Rev 5(5):CD014173, 2026. e-Pub 2026. PMID: 42159078.
- Li Y, Msaouel P, Campbell M, Hwu P, Diab A, Kim ST. Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series. RMD Open. RMD Open 10(3), 2024. e-Pub 2024. PMID: 39214611.
- Keam S, Turner N, Kugeratski FG, Rico R, Colunga-Minutti J, Poojary R, Alekseev S, Patel AB, Li YJ, Sheshadri A, Loghin ME, Woodman K, Aaroe AE, Hamidi S, Iyer PC, Palaskas NL, Wang Y, Nurieva R. Toxicity in the era of immune checkpoint inhibitor therapy, 2024. e-Pub 2024. PMID: 39247203.
- Li YJ, Prieto VG, Tayar J. Case of new-onset scleromyxoedema-scleroedema spectrum disorder in a patient with CLL. RMD Open(9):4, 2023. e-Pub 2023. PMID: 38016711.
- Skaug B, Guo X, Li YJ, Charles J, Pham KT, Couturier J, Lewis DE, Bracaglia C, Caiello I, Mayes MD, Assassi S. Reduced digestion of circulating genomic DNA in systemic sclerosis patients with the DNASE1L3 R206C variant. Rheumatology (Oxford) 62(9):3197-3204, 2023. e-Pub 2023. PMID: 36708011.
- Rees ML, Subramaniam J, Li Y, Hamilton DJ, Frazier OH, Taegtmeyer H. A PKM2 signature in the failing heart. Biochem Biophys Res Commun 459(3):430-6, 2015. e-Pub 2015. PMID: 25735978.
Abstracts
- Li J, Buni M, Lu H, Tayar J, Assassi S. Raynaud’s phenomenon in the setting of immune checkpoint inhibitors: a case series and possible implications. 9th World Congress on Systemic Sclerosis 11(1):194, 2026. e-Pub 2026.
- Keam S, Li Y, Chu Y, Tayar JH, Lu H, Wu M, Agarwal S, Jain N, Msaouel P, Diab A, Haymaker C, Wang L, Nurieva R, Kim ST. Effector CD8+ T Cells and PD-1hiCXCL13hiCD4+ T cells contribute to recurrent immune checkpoint inhibitor mediated inflammatory arthritis. ACR Convergence 2025.
- Thimmapuram R, Buni M, Lu H, Tayar J, Li J, Suarez-Almazor M, Rico R, Turner N, Nurieva R. Identification of Biomarkers Predicting Steroid Resistance in Immune Checkpoint Inhibitor-Induced Arthritis. ACR Convergence 2025.
- Li Y, Leung C, Lopez-Olivio M, Lin H, Tayar JH. A Retrospective Safety Analysis based on Platelets in Arthrocentesis and Joint Injections in Cancer Patients.
Book Chapters
- Li, YJ, Lu, H, Kim, ST, Tannir, NM. Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy, 425-431, 2025.
- Li Y, Kim ST, Tannir, HLu. Chapter 53: SICCA syndrome induced by Immune Checkpoint Inhibitor Therapy. In: Challenging Cases in Immunotherapy Related Organ Toxicities, 2025.
Patient Reviews
CV information above last modified August 28, 2026